8th January 2019: NeRRe Therapeutics CEO, Dr Mary Kerr, presents at the Biotech Showcase, 10:30 Franciscan – D (Ballroom Level), Hilton San [...]
Highly differentiated treatments for common, chronic and debilitating conditions experienced by people worldwide.
A unique approach
NeRRe Therapeutics is a clinical stage company progressing a unique portfolio of three neurokinin-1 antagonists (NK-1RAs) for the treatment of common, chronic and debilitating conditions, caused by neuronal hypersensitivity related to NK-1 receptor system dysfunction. It’s lead compound orvepitant is in a multinational Phase 2b trial in patients suffering from chronic refractory cough, a neuronal hypersensitivity condition for which there are no approved treatments.
For general, media or partnership enquiries, get in touch with us: